Drug Information

Drug General Information
Drug ID
D05KKP
Former ID
DIB004537
Drug Name
PF-06252616
Drug Type
Antibody
Indication Muscular dystrophy [ICD10:G71.0] Phase 2 [525019]
Company
Pfizer
Target and Pathway
Target(s) Growth/differentiation factor 8 Target Info [544346]
PANTHER Pathway TGF-beta signaling pathway
WikiPathways Hypertrophy Model
References
Ref 525019ClinicalTrials.gov (NCT02310763) A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy. U.S. National Institutes of Health.
Ref 544346Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.